Analysts Issue Forecasts for RVMD FY2027 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Equities research analysts at Brookline Capital Markets issued their FY2027 earnings per share estimates for shares of Revolution Medicines in a research report issued on Monday, September 28th. Brookline Capital Markets analyst L. Cann anticipates that the company will post earnings per share of ($5.00) for the year. Brookline Capital Markets has a “Buy” rating and a $318.00 price objective on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($8.87) per share. Brookline Capital Markets also issued estimates for Revolution Medicines’ FY2028 earnings at $0.94 EPS, FY2029 earnings at $8.94 EPS and FY2030 earnings at $18.15 EPS.

Several other research firms have also issued reports on RVMD. HC Wainwright raised their price target on shares of Revolution Medicines from $195.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Sanford C. Bernstein upped their price objective on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. Wedbush increased their target price on shares of Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. Bank of America increased their target price on shares of Revolution Medicines from $225.00 to $265.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Finally, Mizuho lifted their target price on Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Revolution Medicines has an average rating of “Moderate Buy” and a consensus target price of $234.33.

Revolution Medicines Trading Up 1.4%

Shares of RVMD stock opened at $204.48 on Wednesday. Revolution Medicines has a 1 year low of $45.49 and a 1 year high of $224.31. The firm’s fifty day simple moving average is $201.67 and its 200 day simple moving average is $164.83. The firm has a market capitalization of $43.83 billion, a P/E ratio of -23.18 and a beta of 1.40. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the prior year, the business posted ($1.31) earnings per share.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 4,053 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $807,519.72. Following the sale, the chief financial officer directly owned 119,216 shares of the company’s stock, valued at approximately $23,752,595.84. The trade was a 3.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Goldsmith sold 13,988 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total value of $2,786,969.12. Following the completion of the transaction, the insider directly owned 253,342 shares of the company’s stock, valued at approximately $50,475,860.08. The trade was a 5.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 284,682 shares of company stock worth $58,147,464 in the last 90 days. 7.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Revolution Medicines

Several large investors have recently made changes to their positions in the company. Janus Henderson Group PLC lifted its holdings in Revolution Medicines by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company’s stock valued at $980,036,000 after purchasing an additional 947,448 shares during the last quarter. Alphabet Inc. bought a new stake in Revolution Medicines during the second quarter worth about $551,843,000. ABS Investment Management LLC acquired a new stake in shares of Revolution Medicines during the second quarter worth approximately $337,104,000. Geode Capital Management LLC increased its holdings in shares of Revolution Medicines by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,161,963 shares of the company’s stock worth $251,912,000 after buying an additional 16,323 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its stake in shares of Revolution Medicines by 13.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 2,845,013 shares of the company’s stock valued at $226,605,000 after acquiring an additional 331,046 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company’s research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations.

Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers.